Satumomab

Drug Profile

Satumomab

Alternative Names: CYT 103; Indium 111In-satumomab pendetide; OncoScint CR/OV; OncoScint CR103; OncoScint OV103; satumomab pendetide

Latest Information Update: 14 May 2008

Price : $50

At a glance

  • Originator Cytogen Corporation
  • Class Acetic acids; Immunoconjugates; Monoclonal antibodies; Monoclonal antibody diagnostics; Oligopeptides; Polyamines; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Ovarian cancer

Most Recent Events

  • 09 May 2008 Cytogen Corporation is acquired by EUSA Pharma
  • 31 Aug 2004 Aventis merges with Sanofi-Synthelabo to form Sanofi-Aventis
  • 31 Dec 2002 Cytogen discontinues selling satumomab
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top